Saturday, Apr 20, 2024
logo
Update At 14:00    USD/EUR 0,94  ↓-0.0013        USD/JPY 154,56  ↓-0.038        USD/KRW 1.374,43  ↓-3.13        EUR/JPY 164,75  ↑+0.212        Crude Oil 87,20  ↑+0.09        Asia Dow 3.615,48  ↓-65.4        TSE 1.803,00  ↓-5.5        Japan: Nikkei 225 37.068,35  ↓-1011.35        S. Korea: KOSPI 2.591,86  ↓-42.84        China: Shanghai Composite 3.065,26  ↓-8.9636        Hong Kong: Hang Seng 16.224,14  ↓-161.73        Singapore: Straits Times 3,20  ↓-0.009        DJIA 22,20  ↑+0.067        Nasdaq Composite 15.282,01  ↓-319.489        S&P 500 4.967,23  ↓-43.89        Russell 2000 1.947,66  ↑+4.696        Stoxx Euro 50 4.918,09  ↓-18.48        Stoxx Europe 600 499,29  ↓-0.41        Germany: DAX 17.737,36  ↓-100.04        UK: FTSE 100 7.895,85  ↑+18.8        Spain: IBEX 35 10.729,50  ↓-35.5        France: CAC 40 8.022,41  ↓-0.85        

Company Database


KM BIOLOGICS CO., LTD.

about this company

Address:

1-6-1 Okubo, Kita-ku, Kumamoto, 860-8568, Japan

Phone Number:

+81-96-344-2755

Fax Number:

+81-96-300-3395

Company Contact Email:

global-strategy@kmbiologics.com

Website:

https://www.kmbiologics.com/en/

Employees:

2,029 (June 2023)

Capital:

USD 71.4M [Total USD 7.6B for the Meiji group companies] (1USD=140JPY)

Revenue:

USD 306M [Total USD 7.6B for the Meiji group companies] (1USD=140JPY)

Main Clients:

Meiji Seika Pharma

Introduction of your company & business:

KM Biologics supplies first-rate biological products and services with sophisticated skills and knowledge based on over 70 years of combined experience. Our main businesses include the following:

Human Vaccines

Blood Plasma Products

Veterinary Vaccines

Newborn Screening

Mission/Vision:

Our responsibility as disease prevention and treatment professionals is to continuously push the limits of life sciences to shape a healthy future for people around the world.

History:

1945: Establishment of our predecessor, Kaketsuken

1946: Vaccine production for smallpox and cholera, a combined vaccine against typhus and paratyphoid, and a tetanus antitoxin started.

1964: Approval of DPT vaccine.

1988: Launch of Bimmugen – the first Japanese recombinant Hepatitis B vaccine.

1991: Launch of Bolheal – the first Japanese fibrin sealant

2001: Succeeded in full-length cDNA cloning of ADAMTS13

2014: Launch of a new haemostatic treatment for haemophillia patients with inhibitors: Byclot – human coagulation factor VIIa containing factor X

2018: Kaketsuken joined Meiji Group and renamed to KM Biologics.

2023: Approval of Quintovac, a pentavalent vaccine for use in Japan.

Key Products or Services:

Seasonal and pandemic influenza vaccines, Pentavalent vaccine, Japanese encephalitis vaccine, Human coagulation factors, Newborn Screening

Factory Equipment:

Dedicated facilities and equipment for manufacturing various types of vaccines and plasma derived therapies regularly inspected and approved by the Japanese authorities (PMDA).

Technology / R&D activities:

With a commitment to discovery, innovation, and excellence, our scientists carry out cutting-edge research that helps contribute to a healthy future for people around the world.

Inactivated COVID-19 vaccine

Live attenuated tetravalent dengue vaccine

Hexavalent vaccine

Recombinant vaccines

International Operations:

So far KM Biologics has supplied vaccines only in Japan. We are looking for strategic partners to explore the overseas markets.

Business Achievements:

After the 2009 pandemic influenza outbreak, we were the first in the world to establish a domestic vaccine supply system – and today we boast the capability to supply the vaccine to around 57 million people

Awards:

KM Biologics has been included in the list of “Certified Health & Productivity Management Outstanding Organizations Recognition Program” by the Ministry of Economy, Trade and Industry three consecutive years, as a company that has an excellent health and productivity management system in place.

Company Goals & Objectives:

Overseas expansion of registered products and testing systems.

Further broadening of our product portfolio with a focus on immunologic, hematologic and congenital disease area.

Becoming a strategic development, manufacturing and sales partner mainly in Japan and APAC region.

Developing new generation of pharmaceuticals by adoption of new modalities